During 2025, Persica has been featured in a number of publications across national and healthcare trade media following the announcement of positive topline data from the Phase 1b Modic Trial, a randomised, double-blind, placebo-controlled clinical trial assessing the safety and efficacy of PP353 as a treatment for patients with cLBP associated with Modic Type 1 changes. This page collects all of our recent media mentions, allowing you to explore the growing conversation around Persica and our technology.
Scrip: Scrip Asks… What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances
21 February, by Eleanor Malone
Drug Discovery World: Meet the Researcher: Duncan McHale (p. 66)
March Issue, by Megan Thomas
Endpoints News: Persica shares early data for antibiotic in chronic back pain
5 March, by Ayisha Sharma
BioWorld: Persica’s PP-353 wins in back pain, advances to phase III
5 March, by Nuala Moran
FirstWord Pharma: Persica touts upbeat early-stage results for antibiotic-based therapy in back pain
5 March, by Pavan Kamat
The Guardian: New drug for lower back pain could be ‘a gamechanger’
28 March, by Denis Campbell
New York Post: New antibiotic a ‘game changer’ for chronic lower back pain
5 April, by McKenzie Beard
Base to Base biotech podcast: Episode 6: Persica Pharmaceuticals and Caszyme
25 April, Hosted by Jim Cornall
Discovery Matters Podcast: What is pain?
28 May, Hosted by Dodi Axelson and Conor McKechnie
The Bio Report podcast: A Novel Approach to Treating Chronic Low Back Pain
25 June, Hosted by Daniel Levine
Labiotech.eu Beyond Biotech podcast: Persica Pharmaceuticals is treating the cause of chronic lower back pain, not just the symptoms
4 July, Hosted by Dylan Kissane
Drug Discovery World podcast: A non-opioid approach to chronic low back pain
7 August, Hosted by Megan Thomas
Ends
For further information:
ICR Healthcare:
Tracy Cheung, Chris Welsh, Emily Johnson
About Persica Pharmaceuticals
Persica Pharmaceuticals is a clinical-stage biotechnology company developing PP353, a groundbreaking and transformative treatment for chronic Low Back Pain (cLBP) with Modic type 1 changes. Modic changes are a sign of inflammation which is visible, with Magnetic Resonance Imaging (MRI) scans, at the vertebral endplate adjacent to a degenerate lumbar disc, and which can extend into the body of the vertebrae. PP353 is a patented, targeted intradiscal antibiotic injection that is delivered directly to the site of infection. It is a non-opioid treatment which addresses an underlying cause of cLBP, rather than just the symptoms, and reduces the need for repeated antibiotic doses.
About PP353
PP353 (intradiscal linezolid) is a suspension of linezolid powder in a thermosensitive vehicle which is liquid at room temperature but increases in viscosity when injected into the site of infection and warmed to body temperature. This increase in viscosity prevents PP353 from leaking out of the degenerate disc into adjacent tissues during injection. PP353 also contains a radio-opaque dye which allows the physician to use image guidance to make sure the gel is positioned correctly in the target disc on injection.
About chronic Low Back Pain with Modic Type 1 changes
Chronic Low Back Pain (>3 months) with Modic Type 1 changes is a common patient subgroup (~25% of cLBP). These patients are readily identifiable on MRI and typically suffer from moderate to severe persistent pain and disability with limited relief from the current standard of care e.g. physiotherapy and analgesia including opioids with a prevalence of >2 million patients in the US alone. Current treatment options provide only limited short term relief or involve invasive and non-reversable nerve ablation which does not treat the underlying cause of the pathology, a probable bacterial infection of the disc.
Comments are closed.